» Articles » PMID: 18991627

CRM1-mediated Nuclear Export of Proteins and Drug Resistance in Cancer

Overview
Journal Curr Med Chem
Specialty Chemistry
Date 2008 Nov 11
PMID 18991627
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Expression levels of intact tumor suppressor proteins and molecular targets of anti-neoplastic agents are critical in defining cancer cell drug sensitivity; however, the intracellular location of a specific protein may be as important. Many tumor suppressor proteins must be present in the cell nucleus to perform their policing activities or for the cell to respond to chemotherapeutic agents. Nuclear proteins needed to prevent cancer initiation or progression or to optimize chemotherapeutic response include the tumor suppressor proteins p53, APC/beta-catenin, and FOXO family genes; negative regulators of cell cycle progression and survival such as p21(CIP1) and p27(KIP1;) and chemotherapeutic targets such as DNA topoisomerases I and IIalpha. Mislocalization of a nuclear protein into the cytoplasm can render it ineffective as a tumor suppressor or as a target for chemotherapy. Blocking nuclear export of any or all of these proteins may restore tumor suppression or apoptosis or, for topoisomerases I and IIalpha, reverse drug resistance to inhibitors of these enzymes. During disease progression or in response to the tumor environment, cancer cells appear to acquire intracellular mechanisms to export anti-cancer nuclear proteins. These mechanisms generally involve modification of nuclear proteins, causing the proteins to reveal leucine-rich nuclear export signal protein sequences. Subsequent export is mediated by CRM1. This review defines the general processes involved in nuclear export mediated by CRM1/RanGTP (exportin/XPO1), examines the functions of individual tumor suppressor nuclear proteins and nuclear targets of chemotherapy, and explores potential mechanisms of cancer cells to induce export of these proteins. Novel drugs that could potentially counteract nuclear export of specific proteins are also discussed.

Citing Articles

Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?.

Sokolova V, Gruber R, Pammer L, Kocher F, Klieser E, Amann A Mol Biol Rep. 2024; 52(1):87.

PMID: 39729162 PMC: 11680630. DOI: 10.1007/s11033-024-10169-5.


Impact of pan-cancer analysis of the exportins family on prognosis, the tumor microenvironment and its potential therapeutic efficacy.

Peng Y, Li Y, Wang L, Lin S, Xu H Clin Exp Med. 2024; 25(1):18.

PMID: 39708137 PMC: 11663167. DOI: 10.1007/s10238-024-01534-6.


HMGB1 as an extracellular pro-inflammatory cytokine: Implications for drug-induced organic damage.

Yuan J, Guo L, Ma J, Zhang H, Xiao M, Li N Cell Biol Toxicol. 2024; 40(1):55.

PMID: 39008169 PMC: 11249443. DOI: 10.1007/s10565-024-09893-2.


The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.

Lai C, Xu L, Dai S Clin Transl Med. 2024; 14(5):e1684.

PMID: 38783482 PMC: 11116501. DOI: 10.1002/ctm2.1684.


Identifying novel inhibitors targeting Exportin-1 for the potential treatment of COVID-19.

Sharma T, Mondal T, Khan S, Patzi Churqui M, Nystrom K, Thombare K Arch Microbiol. 2024; 206(2):69.

PMID: 38240823 DOI: 10.1007/s00203-023-03761-z.